GGrantIndex
← Search

BREAST CANCER

$0P30FY2002CANIH

Wayne State University, Detroit MI

Investigators

Linked publications, trials & patents

Trial NCT06501040Trial NCT04479267Trial NCT04397679Trial NCT04266522Trial NCT04159896Trial NCT03875053Trial NCT03683420Trial NCT03456804Trial NCT03454529Trial NCT03453489Trial NCT03406858Trial NCT03252600Trial NCT03147885Trial NCT02824029Trial NCT02819024Trial NCT02723604Trial NCT02620865Trial NCT02568449Trial NCT02521090Trial NCT02520115Trial NCT02472275Trial NCT02470559Trial NCT02359019Trial NCT02178436Trial NCT02178163Trial NCT02173093Trial NCT02145078Trial NCT02094872Trial NCT02058706Trial NCT02037256Trial NCT01987596Trial NCT01958372Trial NCT01698658Trial NCT01504711Trial NCT01281163Trial NCT01175980Trial NCT01147016Trial NCT01116232Trial NCT01071564Trial NCT01051570Trial NCT01022138Trial NCT00984919Trial NCT00972023Trial NCT00942422Trial NCT00938626Trial NCT00935090Trial NCT00918762Trial NCT00914147Trial NCT00906503Trial NCT00903214Trial NCT00899665Trial NCT00897910Trial NCT00897741Trial NCT00897494Trial NCT00897247Trial NCT00890617Trial NCT00888654Trial NCT00769288Trial NCT00768118Trial NCT00717535Trial NCT00691015Trial NCT00559897Trial NCT00541099Trial NCT00527124Trial NCT00521261Trial NCT00520767Trial NCT00514215Trial NCT00503841Trial NCT00499694Trial NCT00482846Trial NCT00459121Trial NCT00438204Trial NCT00423826Trial NCT00410904Trial NCT00376948Trial NCT00369109Trial NCT00305747Trial NCT00303901Trial NCT00301808Trial NCT00293384Trial NCT00288028Trial NCT00258466Trial NCT00258310Trial NCT00258284Trial NCT00258245Trial NCT00258232Trial NCT00248560Trial NCT00248482Trial NCT00244946Trial NCT00244933Trial NCT00243048Trial NCT00238329Trial NCT00227721Trial NCT00217581Trial NCT00121264Trial NCT00118157Trial NCT00078923Trial NCT00068653Trial NCT00066326Trial NCT00056004

Abstract

Description: (Applicant's Description) The Breast Cancer Program is integrated and comprehensive spanning basic, translational and clinical research. One area of basic research is focused on understanding the biology of the MCF10AT model of human preneoplastic, proliferative breast disease, which was developed by members of this Program. This xenograft model recapitulates the histological stigmata of early breast cancer development: atypical hyperplasia (AH), carcinoma in situ (CIS) with progression to invasive cancer. Estrogen enhances, and tamoxifen inhibits, both AH and CIS. Translational research utilizes this model as a preclinical test system of prevention agents and strategies. This work is part of an interprogrammatic collaboration with the Molecular Biology and Genetics and the Population Studies and Prevention Programs, ultimately aimed at testing prevention approaches in the community-research setting. Current emphasis is on control of breast cancer risk by dietary modification and chemoprevention. A second area of basic research is steroid and peptide signaling factors and receptors in breast cancer growth and development and the interface of these factors/receptors with each other and in epithelial-stromal interactions. Translational/clinical research efforts are also directed towards development of more efficacious therapy for breast cancer patients. Goals include development of effective biological/immunological based therapy, elucidation of the parameters that lead to a favorable outcome of high dose chemotherapy with autologous stem cell transplantation, and integration of biological therapy into the high dose setting. Basic/translational research in these areas is focused on vaccine development, on in vitro immunization for adoptive immunotherapy and on mechanisms of treatment failure. These studies form the foundation of ongoing and planned clinical trials.

View original record on NIH RePORTER →